Carol Barash, Ph.D.,
Principal

E-Mail:  cbarash@gepci.com

Selected Clients

·         PPD, Inc.  - 2001 

Provided insights into markets barriers and opportunities for physician and consumer acceptance of  pharmacogenetic testing.  Presented strategic approach to PPD, Inc. sponsored symposium on new directions in the field.

·         Berdy Medical Systems, Inc. - 2001

Improved physician office adoption of state- of the- art electronic medical record software with interface to laboratories and pharmacies by writing a comprehensive white paper on office return on investment, creating a highly effective user manual and developing client training that recognized and solved the problems of new users.

·         Genelex, Inc. -  2001

Provided pharmacogenetic business consultation, advised company on current anticipated regulation, pending legislation, and ethical issues, resulting in successful bids for high throughput SNP testing contracts as well as revisions to their state-of the-art, direct to consumer DNA tests. 

·         Orchid Biosciences, Inc. - 2000

Identified current and anticipated ethical issues in business strategies under consideration. Identified conceptual, and pragmatic barriers and opportunities to a direct- to- physician and direct to consumer SNP testing business, resulting in revised business planning and delayed launching.  Developed business plans for products and services to augment the original Web-based business.  Identified experts for medical and ethical advisory boards to the business. Designed and implemented pre-market testing of physician acceptance.  Interviewed candidates for operations manager.   Provided strategies for securing corporate alliances with payors, including but not limited to MCOs and HCFA.  Developed corporate policy on the regulation of home-brew pharmacogenetic tests, and delivered Orchid’s first and second position to the US DHHS Secretary’s Advisory Committee on Genetic Testing, (SACGT), garnered industry interest in submitting a coordinated pharmacogenetic position both to the SACGT as well as to BIO and CLIAA.  Forged strategic alliances with the AMA and GROW  (Genetic Resources on the Web, NIH).  Wrote monograph on ethical issues in clinical pharamacogenetics testing to support both the communications and marketing teams.   

·         Robert Wood Johnson Foundation - 2000

Advised on new directions to expand the foundation’s genetics programs.  Established direction for research and development funding opportunities in genetics education and policy. 

·         Doc.Is, Inc. - 2000

Brokered important business collaborations for Doc.Is with U.S. partners and provided consultations on entering the US market.  Designed research to identify usability barriers in software design and use by practicing physicians.  This enhanced corporate decisions about US marketability.

·         GVO, Inc.  -  1999

Identified barriers and opportunities for adoption of innovative acute coronary syndrome management product by emergency medicine physicians nationwide.  Results led company to reposition the product and overhaul its marketing strategy. 

·         American Medical Association - 1995 - 1999

Conceptualized and developed research projects to assess genetic discrimination experienced by individuals with NF1 and their unaffected family members.  The design served as a model for disorders of highly variable expression.  Recruited to play a key role in the AMA’s Council on Ethical and Judicial Affair’s opinion on genetic testing in children by providing technical assistance, proposing additional areas for Council involvement in this issue, and drafting the report.

·         International Bar Association, Medical Legal Committee  -  1995-1996

Consulted and provided technical expertise for the development of a model law entitled The Human Genome Treaty.

 ·         University of Chicago Law School -1996

Commissioned to write and deliver a paper on genetic testing and children for the Law School’s symposium Genetics and the Law.